Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 0.77 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.77 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.51 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6358994 | 0.91 | POLB (0.84) | POLBHTTL3MBTL1SLC6A2SLC6A4 | |
| SCHEMBL6357908 | 0.91 | POLB (0.84) | POLBHTTL3MBTL1SLC6A2SLC6A4 | |
| SCHEMBL5799968 | 0.88 | POLB (0.78) | POLBHTTL3MBTL1SLC6A2SLC6A4 | |
| SCHEMBL6355077 | 0.87 | HTT (1.00) | POLBHTTL3MBTL1SLC6A2SLC6A4 | |
| SCHEMBL6355088 | 0.87 | HTT (0.82) | POLBHTTL3MBTL1SLC6A2SLC6A4 | |
| SCHEMBL5906459 | 0.86 | POLB (0.74) | POLBHTTL3MBTL1SLC6A2SLC6A4 | |
| SCHEMBL5905875 | 0.81 | POLB (0.67) | POLBHTTL3MBTL1SLC6A2SLC6A4 | |
| SCHEMBL8947354 | 0.79 | POLB (0.65) | POLBHTTL3MBTL1SLC6A2SLC6A4 | |
| SCHEMBL6355877 | 0.76 | P2RX7 (0.76) | POLBHTTL3MBTL1SLC6A2SLC6A4 | |
| SCHEMBL8947234 | 0.75 | POLB (0.60) | POLBHTTL3MBTL1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009812-A1 | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-01-13 | — | — | US | claimed |
| EP-1438973-A1 | REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-07-21 | — | — | EP | claimed |
| WO-2005056609-A1 | CATIONIC OLIGOMER OF A SACCHARIDE FOR RESOLVING ENANTIOMERS AND ASYMMETRIC SYNTHESIS | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2005-06-23 | — | — | WO | disclosed |
| US-20050009812-A1 | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-01-13 | — | — | US | disclosed |
| EP-1438973-A1 | REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009812-A1 | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | TFAM, CYP11B2, CYP11B1 | POLB 1411/4885HTT 761/4885L3MBTL1 2120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.